277 related articles for article (PubMed ID: 11460476)
1. Fibrin formation and proteolysis during ancrod treatment. Evidence for des-A-profibrin formation and thrombin independent factor XIII activity.
Dempfle CE; Argiriou S; Alesci S; Kucher K; Müller-Peltzer H; Rübsamen K; Heene DL
Ann N Y Acad Sci; 2001; 936():210-4. PubMed ID: 11460476
[TBL] [Abstract][Full Text] [Related]
2. Analysis of fibrin formation and proteolysis during intravenous administration of ancrod.
Dempfle CE; Argiriou S; Kucher K; Müller-Peltzer H; Rübsamen K; Heene DL
Blood; 2000 Oct; 96(8):2793-802. PubMed ID: 11023513
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activation without changes in tPA and PAI-1 in response to subcutaneous administration of ancrod.
Dempfle CE; Alesci S; Kucher K; Müller-Peltzer H; Rübsamen K; Borggrefe M
Thromb Res; 2001 Dec; 104(6):433-8. PubMed ID: 11755954
[TBL] [Abstract][Full Text] [Related]
4. The activation of plasma factor XIII with the snake venom enzymes ancrod and batroxobin marajoensis.
Walter M; Nyman D; Krajnc V; Duckert F
Thromb Haemost; 1977 Aug; 38(2):438-46. PubMed ID: 579487
[TBL] [Abstract][Full Text] [Related]
5. The effects of ancrod, the coagulating enzyme from the venom of Malayan pit viper (A. rhodostoma) on prothrombin and fibrinogen metabolism and fibrinopeptide A release in man.
Bell WR; Shapiro SS; Martinez J; Nossel HL
J Lab Clin Med; 1978 Apr; 91(4):592-604. PubMed ID: 641385
[TBL] [Abstract][Full Text] [Related]
6. Ancrod: normalization of fibrinolytic enzyme abnormalities in patients with systemic lupus erythematosus and lupus nephritis.
Glas-Greenwalt P; Kant KS; Dosekun A; Frazier J; Allen C; Pollak VE
J Lab Clin Med; 1985 Jan; 105(1):99-107. PubMed ID: 3871465
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin.
Pizzo SV; Schwartz ML; Hill RL; McKee PA
J Clin Invest; 1972 Nov; 51(11):2841-50. PubMed ID: 4263497
[TBL] [Abstract][Full Text] [Related]
8. Regulation of fibrinogen biosynthesis: effect of fibrin degradation products, low-molecular-weight peptides of fibrinogenolysis, and fibrinopeptides A and B.
Kessler CM; Bell WR
J Lab Clin Med; 1979 May; 93(5):758-67. PubMed ID: 429874
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII.
Greenberg CS; Achyuthan KE; Rajagopalan S; Pizzo SV
Arch Biochem Biophys; 1988 Apr; 262(1):142-8. PubMed ID: 2895608
[TBL] [Abstract][Full Text] [Related]
10. Defibrinogenating enzymes.
Bell WR
Drugs; 1997; 54 Suppl 3():18-30; discussion 30-1. PubMed ID: 9360849
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the factors contributing to fibrin-dependent plasminogen activation.
Mosesson MW; Siebenlist KR; Voskuilen M; Nieuwenhuizen W
Thromb Haemost; 1998 Apr; 79(4):796-801. PubMed ID: 9569195
[TBL] [Abstract][Full Text] [Related]
12. The antiplatelet activity of ancrod on administration to rabbits.
Chang MC; Huang TF
J Lab Clin Med; 1995 Apr; 125(4):508-16. PubMed ID: 7706907
[TBL] [Abstract][Full Text] [Related]
13. A microtiter plate assay for factor XIII A-chain-fibrin interactions.
Achyuthan KE; Santiago MA; Greenberg CS
Anal Biochem; 1994 May; 219(1):43-8. PubMed ID: 8059954
[TBL] [Abstract][Full Text] [Related]
14. The cleavage sequence of fibrinopeptide A from fibrinogen fragment E by thrombin, atroxin or batroxobin.
Meh DA; Siebenlist KR; Bergtrom G; Mosesson MW
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):107-12. PubMed ID: 8457636
[TBL] [Abstract][Full Text] [Related]
15. Coagulation factor XIII variants with altered thrombin activation rates.
Andersen MD; Kjalke M; Bang S; Lautrup-Larsen I; Becker P; Andersen AS; Olsen OH; Stennicke HR
Biol Chem; 2009 Dec; 390(12):1279-83. PubMed ID: 19804366
[TBL] [Abstract][Full Text] [Related]
16. [Interaction of fibrinogen with two forms of fibrin differing in the degree of activation by thrombin].
Belitser VA; Lugovskoĭ EV; Ugarova TP; Derzskaia SG
Biokhimiia; 1985 Aug; 50(8):1336-41. PubMed ID: 4074798
[TBL] [Abstract][Full Text] [Related]
17. Role of plasminogen activator inhibitor-1 in promoting fibrin deposition in rabbits infused with ancrod or thrombin.
Krishnamurti C; Bolan C; Colleton CA; Reilly TM; Alving BM
Blood; 1993 Dec; 82(12):3631-6. PubMed ID: 8260701
[TBL] [Abstract][Full Text] [Related]
18. Ancrod revisited: viscoelastic analyses of the effects of Calloselasma rhodostoma venom on plasma coagulation and fibrinolysis.
Nielsen VG
J Thromb Thrombolysis; 2016 Aug; 42(2):288-93. PubMed ID: 26905070
[TBL] [Abstract][Full Text] [Related]
19. Fibrinogen assembly and crosslinking on a fibrin fragment E template.
Mosesson MW; Siebenlist KR; Hernandez I; Wall JS; Hainfeld JF
Thromb Haemost; 2002 Apr; 87(4):651-8. PubMed ID: 12008948
[TBL] [Abstract][Full Text] [Related]
20. [Activation of factor XIII by beta-thrombin].
Umarova BA; Strukova SM
Biokhimiia; 1979 Aug; 44(8):1524-9. PubMed ID: 497297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
